

CITATION REPORT

List of articles citing

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

DOI: 10.1016/s0735-1097(03)00555-2

Journal of the American College of Cardiology, 2003, 42, 158-64.

Source: <https://exaly.com/paper-pdf/35369864/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
340	What's new in Rheumatology and Autoimmune Diseases. 2002 , 30, i-iii		
339	Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. 2003 , 4, 488-96		31
338	Treatment of Pulmonary Arterial Hypertension with Sildenafil. 2004 , 39, 243-253		2
337	Rosiglitazone for Treatment of HIV Lipodystrophy. 2004 , 141, 739		
336	To Butterfly or To Needle: The Specimen Testing Question. 2004 , 141, W-140		1
335	Low-Carbohydrate Diets. 2004 , 141, 738		
334	Residents' work hours. 2004 , 141, 740; author reply 742		
333	Tadalafil in primary pulmonary arterial hypertension. 2004 , 141, 743-4		40
332	[Vasoactive intestinal polypeptide in the respiratory tract: physiology and pathophysiology]. 2004 , 58, 330-8		7
331	Advancing therapy for pulmonary arterial hypertension: can animal models help?. 2004 , 169, 5-6		11
330	Sildenafil for pulmonary arterial hypertension: still waiting for evidence. 2004 , 169, 6-7		17
329	Combination therapy for pulmonary arterial hypertension: still more questions than answers. 2004 , 24, 339-40		21
328	Natriuretic peptides, respiratory disease, and the right heart. 2004 , 126, 1330-6		119
327	Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. 2004 , 24, 1007-10		219
326	Phosphodiesterase inhibitors in the management of primary pulmonary hypertension. 2004 , 19, 74-9		1
325	Pulmonary hypertension. 2004 , 29, 575-634		16
324	B-type natriuretic Peptide and the right heart. 2004 , 9, 99-105		21

323	Role of the cardiologist: Clinical aspects of managing erectile dysfunction. 2004 , 27, 3-7		7
322	Therapie der pulmonalen Hypertonie. 2004 , 1, 95-101		2
321	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. 2004 , 25, 2243-78		665
320	Echocardiography in pulmonary vascular disease. 2004 , 22, 383-99, vi		32
319	Traitement de l'hypertension artérielle pulmonaire de l'enfant. 2004 , 11, 945-945		
318	Efficacy of Oral Sildenafil as Rescue Therapy in Patients With Severe Pulmonary Arterial Hypertension Chronically Treated With Prostacyclin. Long-Term Results. 2004 , 57, 946-951		2
317	Recent advances in the treatment of pulmonary arterial hypertension. 2004 , 1, 129-135		1
316	End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 48S-55S	15.1	109
315	Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 68S-72S	15.1	108
314	Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 81S-88S	15.1	137
313	Sildenafil for pulmonary hypertension. 2004 , CD003562		12
312	Eficacia del sildenafil por vía oral como terapia de rescate en pacientes con hipertensión arterial pulmonar severa en tratamiento crónico con prostaciclina. Resultados a largo plazo. 2004 , 57, 946-951		1
311	Treatment of pulmonary arterial hypertension. 2004 , 351, 1425-36		1338
310	The discovery and development of Viagra® (sildenafil citrate). 2004 , 1-13		4
309	[Primary pulmonary hypertension: prospects for treatment]. 2004 , 122, 62-3		1
308	Diagnosis and treatment of pulmonary arterial hypertension. 2004 , 22, 441-52, vii		5
307	[Treatment of pulmonary arterial hypertension associated to systemic sclerosis]. 2004 , 25, 195-200		2
306	[Treatments for pulmonary arterial hypertension]. 2004 , 25, 720-31		2

305	[Treatment of pulmonary arterial hypertension in children]. 2004 , 11, 945-50	8
304	Myocardial and pulmonary effects of aqueous oxygen with acute hypoxia. 2004 , 78, 956-60; discussion 956-60	6
303	Portopulmonary hypertension and hepatopulmonary syndrome. 2004 , 363, 1461-8	356
302	Current World Literature. 2004 , 13, 575-588	
301	Bibliography Current World Literature. 2004 , 16, 238-279	
300	Inhaled alternatives to nitric oxide. 2005 , 33, S188-95	27
299	Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. 2005 , 128, 622S	19
298	Endothelin receptor antagonists: clinical realities and future directions. 2005 , 45, 182-91	36
297	Efficacy of acute inhalation of nitric oxide in patients with primary pulmonary hypertension using chronic use of continuous epoprostenol infusion. 2005 , 69, 335-8	6
296	Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. 2005 , 69, 461-5	45
295	[Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis]. 2005 , 64, 123-36	2
294	Current treatment strategies for pulmonary arterial hypertension. 2005 , 258, 199-215	51
293	Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. 2005 , 130, 445-53	170
292	Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. 2005 , 30, 451	22
291	Topical tacrolimus in the treatment of annular erythema associated with Sjögren's syndrome. 2005 , 30, 450-1	9
290	Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. 2005 , 510, 87-96	16
289	Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. 2005 , 96, 1334-6	76
288	Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. 2005 , 96, 47M-51M	150

287 Hipertensi3 arterial pulmonar en el a3 2004. **2005**, 5, 90A-103A

286 Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction. **2005**, 2, 407-14 15

285 Combination drug therapy in the management of pulmonary arterial hypertension. **2005**, 20, 177-82 4

284 [Therapy of pulmonary arterial hypertension]. **2005**, 46, 341-9 0

283 [Treatment algorithm for pulmonary arterial hypertension]. **2005**, 30, 326-31 1

282 [Emerging therapies for the treatment of pulmonary arterial hypertension]. **2005**, 30, 296-302 1

281 Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan. **2005**, 155, 376-80 16

280 Initial experience with bosentan (Tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children. **2005**, 94, 570-4 18

279 Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. **2005**, 3, 26 26

278 One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. **2005**, 38, 185-95 36

277 Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. **2005**, 111, 3274-80 203

276 Pulmonary artery hypertension: new drug treatment in children. **2005**, 90, ep15-ep20 1

275 Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil?. **2005**, 94, 774-7 24

274 [A role for combination therapy in pulmonary arterial hypertension]. **2005**, 59, 730-5 2

273 Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension. **2005**, 67, 251-84 8

272 Pulmonary arterial hypertension: the race for the most effective treatment. **2005**, 171, 1199-201 14

271 Prostacyclin therapy for pulmonary arterial hypertension: new directions. **2005**, 26, 394-401 18

270 Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. **2005**, 6, 1921-30 15

269	Inhaled iloprost in pulmonary arterial hypertension. 2005 , 39, 1265-74	28
268	Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. 2005 , 112, 423-31	212
267	Advances in the medical treatment of pulmonary hypertension. 2005 , 28, 311-24	4
266	[Treatment of pulmonary arterial hypertension]. 2005 , 34, 1445-55	2
265	Sildenafil citrate therapy for pulmonary arterial hypertension. 2005 , 353, 2148-57	1843
264	Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. 2005 , 32, 419-29, vi	34
263	Sildenafil for pulmonary hypertension. 2005 , 39, 869-84	34
262	[Guidelines on diagnosis and treatment of pulmonary arterial hypertension]. 2005 , 58, 523-66	21
261	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. 2005 , 6, 76	25
260	Drug treatment of pulmonary arterial hypertension: current and future agents. 2005 , 65, 1337-54	40
259	Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar. 2005 , 58, 523-566	
258	Iloprost for idiopathic pulmonary arterial hypertension. 2005 , 3, 215-23	7
257	Cold hands--strained heart? Advances in the management of Raynaud's phenomenon and pulmonary hypertension. 2005 , 7, 126-8	2
256	Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors. 2006 , 5, 271-82	8
255	Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. 2006 , 20, 722-35	22
254	[Pulmonary arterial hypertension and systemic sclerosis]. 2006 , 35, 1929-37	18
253	Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. 2006 , 114, 1482-9	489
252	Combination Therapy With Bosentan and Sildenafil in Idiopathic Pulmonary Arterial Hypertension. 2006 , 2006, 166-167	

251	Hypertension artérielle pulmonaire. 2006 , 3, 1-27	2
250	Safety and Tolerability of Bosentan in Adults With Eisenmenger Physiology. 2006 , 2006, 165-167	
249	Pulmonary arterial hypertension. 2006 , 12, 228-34	14
248	Nebulizer Therapy in Pulmonology: Review of the Literature. 2006 , 2, 211-235	
247	Pharmacologic treatment for pulmonary arterial hypertension. 2006 , 21, 561-8	9
246	An evidence-based approach to the management of pulmonary arterial hypertension. 2006 , 21, 385-92	27
245	Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. 2006 , 25, 214-26	19
244	Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. 2006 , 36 Suppl 3, 16-24	49
243	First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. 2006 , 36 Suppl 3, 32-8	54
242	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702	366
241	[Pulmonary arterial hypertension in collagenoses: clinical features, epidemiology, pathogenesis, diagnosis and treatment]. 2006 , 65, 297-300, 302-5	2
240	New insights in the treatment strategy for pulmonary arterial hypertension. 2006 , 20, 377-86	23
239	[Rheumatology-part 2. Research news concerning pathogenesis, epidemiology, diagnosis, and therapy of connective tissue disease]. 2006 , 101, 127-37	0
238	[Pulmonary hypertension: the future has begun]. 2006 , 101, 328-33	1
237	Pulmonale Hypertonie im Kindesalter. 2006 , 2, 177-193	
236	[Reverse remodeling -- paradigm shift in the treatment of pulmonary hypertension]. 2006 , 131, 871-4	2
235	[Diagnosis and treatment of pulmonary hypertension]. 2006 , 60, 428-40; quiz 441-2	2
234	Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. 2006 , 174, 1257-63	465

233	[Diagnosis and treatment of pulmonary hypertension]. 2006 , 131, 635-8	2
232	[Diagnosis and therapy of chronic pulmonary hypertension]. 2006 , 60, 749-71	27
231	Sildenafil for pulmonary arterial hypertension. 2006 , 2, 137-43	1
230	Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. 2006 , 28, 691-4	203
229	Hypoxia- and non-hypoxia-related pulmonary hypertension - established and new therapies. 2006 , 72, 30-40	36
228	Sildenafil treatment for portopulmonary hypertension. 2006 , 28, 563-7	168
227	Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment. 2006 , 45 Suppl 4, iv22-5	24
226	Management of Vasculopathy in Connective Tissue Disease. 2006 , 2, 269-278	
225	Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. 2006 , 21, 194-200	46
224	Treatment for Pulmonary Arterial Hypertension. 2006 , 99-118	1
223	Classification and Prognosis of Pulmonary Arterial Hypertension. 2006 , 66-82	1
222	Emerging treatments for pulmonary arterial hypertension. 2006 , 11, 609-19	5
221	Sildenafil for pulmonary arterial hypertension: when blue turns into white. 2006 , 7, 1801-10	4
220	Emerging therapies for pulmonary arterial hypertension. 2007 , 16, 803-18	12
219	Current therapies for pulmonary arterial hypertension. 2007 , 11, 137-48	3
218	Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. 2007 , 115, 2331-9	118
217	Idiopathic pulmonary arterial hypertension and inhaled iloprost: good night rebound effects?. 2007 , 74, 496-7	3
216	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. 2007 , 15, 76-86	52

215	Management of pulmonary arterial hypertension with a focus on combination therapies. 2007 , 26, 437-46	59
214	Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. 2007 , 118, 178-82	31
213	Prostanoid therapy for pulmonary arterial hypertension. 2007 , 28, 127-42; ix	24
212	Combination therapy and new types of agents for pulmonary arterial hypertension. 2007 , 28, 169-85, ix	41
211	Pulmonary Hypertension. 2007 ,	
210	Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006. 2007 , 37, 38-48	14
209	Traitement médical de l'hypertension artérielle pulmonaire. 2007 , 56, S123-S136	
208	Therapeutic challenges for systemic sclerosis: facts and future targets. 2007 , 1110, 448-54	8
207	[Novel indications for phosphodiesterase type 5 inhibitors]. 2007 , 102, 617-30	4
206	Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. 2007 , 96, 211-7	29
205	[Diagnosis and therapy of chronic pulmonary hypertension]. 2007 , 96, 301-30	22
204	[Fast and efficient healing of scleroderma-associated acral ulcers with sildenafil]. 2008 , 59, 230-2	7
203	Bewegungstherapie bei pulmonaler Hypertonie. 2008 , 5, 98-102	
202	Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications. 2008 , 153 Suppl 1, S99-S111	97
201	Novel approach with intratracheal administration of microgelatin hydrogel microspheres incorporating basic fibroblast growth factor for rescue of rats with monocrotaline-induced pulmonary hypertension. 2008 , 136, 1250-6	8
200	Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger syndrome. 2008 , 68, 1049-66	120
199	Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 161-9	15.1 162
198	Medical therapy for pulmonary arterial hypertension. 2008 , 9, 65-81	7

197	Pulmonary Hypertension. 2008 ,	3
196	Therapeutic advances in pulmonary arterial hypertension. 2008 , 2, 249-65	30
195	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. 2008 , 21, 824-32	57
194	Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. 2008 , 8, 171-85	39
193	Prostacyclin therapies for the treatment of pulmonary arterial hypertension. 2008 , 31, 891-901	197
192	Iloprost in pulmonary hypertension. 2008 , 2, 689-702	3
191	Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. 2008 , 63 Suppl 2, ii1-ii41	26
190	Pulmonary Arterial Hypertension. 2008 , 759-771	
189	Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. 2008 , 94 Suppl 1, i1-41	45
188	Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. 2008 , 32, 198-209	101
187	[Combination therapy in patients with pulmonary arterial hypertension]. 2008 , 133 Suppl 6, S187-90	0
186	Inhaled prostanoids in the therapy of pulmonary hypertension. 2008 , 21, 1-12	67
185	Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. 2008 , 149, 521-30	437
184	Current pharmacological treatment of pulmonary arterial hypertension. 2008 , 3, 11-9	10
183	Arterial pulmonary hypertension in noncardiac intensive care unit. <i>Vascular Health and Risk Management</i> , 2008 , 4, 1043-60	4.4 31
182	Review of inhaled iloprost for the control of pulmonary artery hypertension in children. <i>Vascular Health and Risk Management</i> , 2009 , 5, 325-31	4.4 38
181	Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. 2009 , 3, 269-87	35
180	Inhaled iloprost for the control of pulmonary hypertension. <i>Vascular Health and Risk Management</i> , 2009 , 5, 465-74	4.4 24

179	Guidelines for the diagnosis and treatment of pulmonary hypertension. 2009 , 34, 1219-63	919
178	Inhalative iloprost - pharmacology and clinical application. 2009 , 10, 2195-207	17
177	Advances in therapies for pediatric pulmonary arterial hypertension. 2009 , 3, 265-82	4
176	Pulmonary Arterial Hypertension in Connective Tissue Diseases. 2009 , 5, 115-119	
175	PDE5 inhibitors in non-urolological conditions. 2009 , 15, 3521-39	24
174	Pulmonary arterial hypertension in human immunodeficiency virus infection. 2009 , 121, 56-67	7
173	Recent Advances in the Management of Pulmonary Arterial Hypertension. 2009 , 5, 41-48	
172	Medical treatment of pulmonary arterial hypertension. 2009 , 30, 484-92	6
171	Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. 2009 , 7, 589-96	16
170	The use of combination therapy in pulmonary arterial hypertension: new developments. 2009 , 18, 148-53	24
169	Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence. 2009 , 34, 7-9	3
168	Pulmonary hypertension in bronchopulmonary dysplasia. 2009 , 27, 43-48	35
167	Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. 2009 , 154, 379-84, 384.e1-2	196
166	Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension. 2009 , 53, 374-80	9
165	Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. 2009 , 14, 284-90	15
164	[Combination therapy for pulmonary arterial hypertension]. 2009 , 45, 36-40	1
163	Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. 2009 , 15, 30-6	74
162	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. 2009 , 26, 813-25	75

161	[Pulmonary arterial hypertension related to systemic sclerosis in 2008]. 2009 , 34, 7-15	1
160	Preserved pulmonary vasodilative properties of aerosolized brain natriuretic peptide. 2009 , 22, 548-53	1
159	Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. 2009 , 361, 1864-71	167
158	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). 2009 , 30, 2493-537	2531
157	End points and clinical trial design in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2009 , 54, S97-S107	15.1 166
156	Combination Therapy for Pulmonary Arterial Hypertension. 2009 , 45, 36-40	
155	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. 2009 , 62, 1464.e1-1464.e58	1
154	cGMP: Generators, Effectors and Therapeutic Implications. 2009 ,	13
153	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. 2009 , 62, 1464.e1-1464.e58	3
152	Pharmacotherapeutic management of pulmonary arterial hypertension. 2010 , 18, 148-62	47
151	Pharmacologic and pharmacokinetic rationale for combination therapy in pulmonary arterial hypertension. 2010 , 56, 686-95	3
150	Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease. 2010 , 6, 13-31	15
149	Role of combination therapy in the treatment of pulmonary arterial hypertension. 2010 , 30, 390-404	7
148	Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. 2010 , 2, 151-61	18
147	Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. 2010 , 4, 61-70	28
146	Therapeutic approaches in adults with congenital heart disease-associated pulmonary arterial hypertension. 2010 , 19, 300-7	6
145	Tadalafil for the treatment of pulmonary arterial hypertension. 2010 , 11, 127-32	27
144	Clinical use of sildenafil in pulmonary artery hypertension. 2010 , 4, 13-9	11

143	Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. 2010 , 122, 88-95		78
142	[Diagnosis and medical treatment of pulmonary arterial hypertension]. 2010 , 99, 107-15		1
141	[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension]. 2010 , 10 Suppl 2, 16-8		3
140	[Pulmonary hypertension - historical development, current therapy and perspectives]. 2010 , 64, 577-82		3
139	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. 2010 , 104 Suppl 1, S74-80		9
138	Current and future therapy for pulmonary hypertension in patients with right and left heart failure. 2010 , 8, 241-50		2
137	Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 2511-9	15.1	564
136	Phosphodiesterases as Drug Targets. 2011 ,		20
135	Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. 2011 , 30, 1327-33		69
134	Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. 2011 , 24, 169-73		7
133	Role of phosphodiesterases in adult-onset pulmonary arterial hypertension. 2011 , 279-305		6
132	Inhaled iloprost for therapy in pulmonary arterial hypertension. 2011 , 5, 145-52		8
131	Tadalafil for the treatment of pulmonary arterial hypertension. 2011 , 5, 315-28		7
130	The management of acute pulmonary arterial hypertension. 2011 , 29, 153-75		19
129	Aerosol drug delivery: developments in device design and clinical use. 2011 , 377, 1032-45		332
128	Therapeutic Options for the Treatment of Pulmonary Hypertension. 2011 , 6, 37-40		
127	Therapeutic strategies in pulmonary hypertension. 2011 , 2, 21		10
126	Sildenafil up-regulates Kv1.5 mRNA expression in rats with pulmonary hypertension. 2011 , 5, 2094-2099		

125 Pulmonary vasodilators. 767-782

124 Pulmonary hypertension: role of combination therapy. **2011**, 9, 457-64

2

123 Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. **2011**, 41, 235-44

21

122 Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. **2011**, 17, 25-33

23

121 Evaluation and Management of the Adult Patient With Pulmonary Hypertension. **2011**, 7, 409-416

2

120 Combination therapy in pulmonary arterial hypertension: do we have the right strategy?. **2011**, 5, 191-205

5

119 Pediatric pulmonary arterial hypertension: current and emerging therapeutic options. **2011**, 12, 1845-64

3

118 Advances in the management of pediatric pulmonary hypertension. **2011**, 56, 1314-39; discussion 1339-40

32

117 Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds. **2011**, 5, 163-71

15

116 HIV infection and pulmonary arterial hypertension. **2011**, 5, 257-66

11

115 Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. **2011**, 140, 1274-1283

187

114 Pulmonary Vascular Disease and Bronchopulmonary Dysplasia: Evaluation and Treatment of Pulmonary Hypertension. **2011**, 12, e645-e651

8

113 Combination therapy for the treatment of pulmonary arterial hypertension. **2011**, 5, 419-30

18

112 WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. **2012**, 55, 89-103

18

111 Inhalation therapy to treat pulmonary arterial hypertension. **2012**, 1, 577-88

4

110 Pulmonary hypertension-"state of the art" management in 2012. **2012**, 64, 60-73

2

109 Pharmacotherapy for pulmonary arterial hypertension. **2012**, 8, 385-402


108 Orienta es para o diagn stico e tratamento da hipertens o pulmonar. **2012**, 31, 71-115

107	Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. 2012 , 106, 730-9	20
106	Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. 2012 , 155, 378-82	84
105	Update on pulmonary arterial hypertension in children: management strategies and clinical utility of sildenafil. 2012 , 59	
104	Inhaled low-dose iloprost for pulmonary hypertension: a prospective, multicenter, open-label study. 2012 , 35, 365-70	5
103	Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome. 2012 , 33, 744-8	14
102	Portopulmonary hypertension. 2013 , 34, 719-37	5
101	Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation. 2013 , 45, 2347-50	9
100	Pharmacotherapy of Pulmonary Hypertension. 2013 ,	2
99	Pulmonary arterial hypertension. 2013 , 8, 97	168
98	Pediatric pulmonary arterial hypertension. 2013 , 15, 606-13	4
97	Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. 2013 , 19, 2213-31	57
96	Combination therapy in pulmonary arterial hypertension. 2013 , 111, 16C-20C	10
95	Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. 2013 , 111, 1A-16A; quiz 17A-19A	48
94	Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension. 2013 , 58, 211-8	16
93	Combination therapy in pulmonary arterial hypertension. 2013 , 34, 841-55	11
92	Pulmonary Hypertension and the Interdependence of Ventricular Function: Part 2: Evaluating the Medical and Surgical Management. 2013 , 4, 191-197	
91	Evidence of synergistic/additive effects of sildenafil and erythropoietin in enhancing survival and migration of hypoxic endothelial cells. 2013 , 304, L230-9	15
90	Combination pharmacotherapy in the treatment of pulmonary arterial hypertension: continuing education article. 2013 , 26, 18-28	2

- 89 Iloprost as Adjuvant to Sildenafil in Connective Tissue Disease-Associated Pulmonary Hypertension. **2013**,
- 88 Combination therapy in the management of pulmonary arterial hypertension. **2013**, 67, 13-23 16
- 87 Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers. **2013**, 61, 444-51 8
- 86 Recent strategies in treatment of pulmonary arterial hypertension, a review. **2015**, 7, 307-22 16
- 85 Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies. **2014**, 2014, 743868 8
- 84 Pulmonary hypertension and pregnancy: an overview. **2014**, 57, 806-26 14
- 83 Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension. **2014**, 9, S79-91 4
- 82 Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Intensive care management of pulmonary hypertension. **2014**, 9, S121-6 4
- 81 Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. **2014**, 33, 689-97 14
- 80 Pulmonary hypertension and breathlessness: is it a combination we can ignore?. **2014**, 44, 114-23 4
- 79 Pulmonary Hypertension. **2014**, 263-281
- 78 Inhaled therapy for the management of perioperative pulmonary hypertension. **2015**, 18, 394-402 14
- 77 Interventions for treating pulmonary hypertension in people with sickle cell disease or thalassaemia. **2015**,
- 76 Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?". **2015**, 7, 544-54 7
- 75 Diagnosis and Management of Pulmonary Hypertension. *Respiratory Medicine*, **2015**, 0.2
- 74 Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. **2015**, 132, 2037-99 624
- 73 Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension. **2015**, 240, 121-7 8
- 72 Use of outcome measures in pulmonary hypertension clinical trials. **2015**, 170, 419-29.e3 12

71	Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension. 2015 , 15, 34	21
70	Current Treatment Strategies, Guidelines and New Therapies. 2015 , 81-145	
69	Treatment of Pulmonary Hypertension. 2015 ,	1
68	Use of inhaled iloprost in children with pulmonary hypertension. 2015 , 50, 370-9	5
67	Pulmonary Hypertension - New Trends of Diagnostic and Therapy. 2016 , 70, 303-307	8
66	Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study. 2016 , 16, 5	8
65	Perioperative Care of the Liver Transplant Patient. 2016 , 32, 453-73	12
64	An Update on the Management of Pulmonary Arterial Hypertension and the Pharmacist's Role. 2016 , 29, 67-76	9
63	A review of therapeutic agents for the management of pulmonary arterial hypertension. 2017 , 11, 46-63	8
62	Sildenafil in the Treatment of Postoperative Hypoxemia with High Resistance in Cyanotic Congenital Heart Disease. 2017 , 13, 140-147	
61	Liver Transplantation: Perioperative Considerations. 2018 , 269-289	1
60	Critical Care. 2018 , 209-215	
59	Chronic Right Heart Failure: Expanding Prevalence and Challenges in Outpatient Management. 2018 , 14, 413-423	3
58	Inhalation of repurposed drugs to treat pulmonary hypertension. 2018 , 133, 34-44	11
57	Early Postoperative Management. 2019 , 205-222	
56	Iloprost delivered via the BREELIB nebulizer: a review of the clinical evidence for efficacy and safety. 2019 , 13, 1753466619835497	5
55	Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. 2019 , 302, 126-139	29
54	Heart Failure. 2019 ,	

53	Sildenafil for Pulmonary Arterial Hypertension. 2019 , 26, e520-e526		19
52	Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. 2019 , 275, 158-164		7
51	Inhaled Iloprost and Oral Sildenafil Combination Therapy: Is it a Chance for Heart Transplant Candidacy?. 2020 , 29, 1039-1045		
50	Formulation and optimization of sildenafil citrate-loaded PLGA large porous microparticles using spray freeze-drying technique: A factorial design and in-vivo pharmacokinetic study. 2021 , 597, 120320		6
49	Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways. 2021 , 26, 453-462		4
48	Transitions and Combination Therapy for Pulmonary Arterial Hypertension. 2008 , 337-362		1
47	Modulating cGMP to treat lung diseases. 2009 , 469-83		8
46	Prostacyclins. 2013 , 218, 177-98		4
45	New Developments in the Pathogenesis and Management of Neonatal Pulmonary Hypertension. 2008 , 241-299		4
44	[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. <i>Archivos De Cardiologia De Mexico</i> , 2015 , 85, 215-24	0.2	6
43	Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan. 2006 , 99, 880-3		14
42	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. 2011 , 121, 2888-97		70
41	Review of the diagnosis and pharmacological management of pulmonary arterial hypertension in connective tissue disease. 2016 , 16, 14-22		1
40	In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension. <i>Anais Da Academia Brasileira De Ciencias</i> , 2020 , 92, e20191445	1.4	1
39	[A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?]. <i>Terapevticheskii Arkhiv</i> , 2017 , 89, 100-103	0.9	2
38	Sildenafil in the treatment of pulmonary hypertension. <i>Vascular Health and Risk Management</i> , 2006 , 2, 411-22	4.4	88
37	What's on the Horizon in Therapy, From Current Approaches to Experimental Agents. <i>Advances in Pulmonary Hypertension</i> , 2003 , 2, 9-16	0.5	2
36	Combination Therapy for PAH: Current Rationale, Future Concepts. <i>Advances in Pulmonary Hypertension</i> , 2006 , 5, 18-22	0.5	1

35	Evaluating Recent Therapeutic Trials in Pulmonary Arterial Hypertension: Raising the Bar for Clinical Investigation. <i>Advances in Pulmonary Hypertension</i> , 2009 , 8, 24-31	0.5	1
34	Pulmonary hypertension in infants with bronchopulmonary dysplasia. <i>Korean Journal of Pediatrics</i> , 2010 , 53, 688-93	2.4	43
33	Clinical efficacy, safety, tolerability, and survival outcome of long-term inhaled iloprost treatment in the management of pulmonary arterial hypertension: Data from prospective multicenter observational OPTION study. <i>Anatolian Journal of Cardiology</i> , 2021 , 25, 721-732	0.8	0
32	Sildenafil citrate: a 5-year update on the worldwide treatment of 20 million men with erectile dysfunction. 2004 , 35-47		
31	NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. 2004 , 163-168		
30	Hypertension artérielle pulmonaire idiopathique. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2005 , 189, 523-534	0.1	
29	Porto-pulmonary hypertension and hepatopulmonary syndrome in patients with hepatic cirrhosis. <i>Pulmonologiya</i> , 2005 , 132-136	0.8	
28	 <i>Pulmonologiya</i> , 2006 , 103-107	0.8	
27	The etiology and pathogenesis of pulmonary arterial hypertension. <i>Cor Et Vasa</i> , 2006 , 48, 108-113	0.3	2
26	Advances in Prostanoid Therapy: New Studies, New Methods of Delivery. <i>Advances in Pulmonary Hypertension</i> , 2006 , 5, 23-30	0.5	1
25	Combination Therapies in Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2008 , 7, 235-242	0.5	0
24	Lungengefäßkrankungen. 2008 , 433-528		
23	Inhaled Prostanoids in the Therapy of Pulmonary Hypertension. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2008 , 080116123756336-12		
22	Chronic Pulmonary Hypertension. 2009 , 483-505		
21	Cor Pulmonale. 2010 , 1326-1355		
20	Combination Therapy for Pulmonary Arterial Hypertension. 2011 , 1509-1520		
19	Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. 2011 , 1477-1485		
18	Prostacyclin and Prostaglandins. 2011 , 1451-1463		

- 17 Critical Care. **2011**, 121-125
- 16 Approach to the Child With Pulmonary Hypertension and Bronchopulmonary Dysplasia. *Advances in Pulmonary Hypertension*, **2011**, 10, 98-103 0.5 1
- 15 Krankheiten des Herzens. **2012**, 335-393
- 14 Selective Pulmonary Vasodilators. **2015**, 809-836
- 13 [Clinical utility of inhaled iloprost in pulmonary arterial hypertension]. *Archivos De Cardiologia De Mexico*, **2014**, 84, 202-10 0.2 1
- 12 Effect of sildenafil on clinical evidence and hemodynamic parameters in patients with pulmonary arterial hypertension, associated with systemic rheumatic diseases. *Systemic Hypertension*, **2014**, 11, 61-66^{1.6}
- 11 Combination Therapy for the Treatment of Pulmonary Arterial Hypertension. *Respiratory Medicine*, **2015**, 377-396 0.2
- 10 [Survival in pulmonary arterial hypertension, associated with connective tissue diseases, treated by sildenafil: results of the prospective study]. *Terapevticheskii Arkhiv*, **2015**, 87, 62-67 0.9
- 9 Idiopathic pulmonary arterial hypertension: current approach to diagnosis and pharmacological treatment. *Pulmonologiya*, **2017**, 27, 216-231 0.8 1
- 8 Chronic Pulmonary Hypertension. **2020**, 465-489
- 7 Krankheiten des Herzens. **2008**, 311-373
- 6 A review of pulmonary arterial hypertension: Part 2: Current and expected treatments. *Netherlands Heart Journal*, **2004**, 12, 337-342 2.2
- 5 A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension. *Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery*, **2010**, 26, 206-218 0 1
- 4 Pulmonary hypertension: current issues of diagnosis and treatment. *Eurasian Heart Journal*, **2011**, 6-12 0.7
- 3 A novel role of Nano selenium and sildenafil on streptozotocin-induced diabetic nephropathy in rats by modulation of inflammatory, oxidative, and apoptotic pathways. *Life Sciences*, **2022**, 120691 6.8 3
- 2 Cor pulmonale (akut und chronisch) [Begutachtung]. *Springer Reference Medizin*, **2022**, 1-7 0
- 1 Theranostic applications of nanoemulsions in pulmonary diseases. **2023**, 177-216 0